Berndt, Lioba C. S., Diebel, Rosina M., Donnelly, Nicholas A., Hall, Jeremy ORCID: https://orcid.org/0000-0003-2737-9009, van den Bree, Marianne B. M. ORCID: https://orcid.org/0000-0002-4426-3254, Adams, Rick A., Shaw, Alexander D. ORCID: https://orcid.org/0000-0001-5741-7526 and Jones, Matt W.
2026.
Sleep as a window into thalamocortical pathology: generative modeling implicates NMDA receptor hypofunction in 22q11.2 deletion syndrome.
Translational Psychiatry
10.1038/s41398-026-04368-w
|
|
PDF
- Published Version
Available under License Creative Commons Attribution. Download (1MB) |
Abstract
22q11.2 deletion syndrome (22q11.2DS) is a strong genetic risk factor for neuropsychiatric conditions, including schizophrenia, yet the underlying synaptic mechanisms remain unclear. Sleep EEG suggests thalamocortical dysfunction, but scalp data alone lack mechanistic resolution. Computational modelling can bridge this gap by inferring receptor-level dynamics from EEG. We applied a conductance-based thalamocortical Dynamic Causal Model (DCM) to sleep-wake EEG from children with 22q11.2DS (n=28) and their neurotypical siblings (n=17), estimating contributions of AMPA, NMDA, GABAA, and GABAB conductances. Building on these estimates, we investigated which receptor systems, if perturbed, could shift circuit dynamics toward sibling patterns. To address this, we implemented in silico pharmacology by systematically scaling receptor-mediated conductances. Increasing NMDA receptor (NMDA-R) efficacy consistently produced the strongest improvements in alignment with sibling spectra (effect size = 0.32 in light NREM, 0.45 in deep NREM), whereas AMPA- or GABA-based manipulations were weaker. The most influential pathways were recurrent NMDA-R excitation among superficial pyramidal cells and NMDA-R excitation from spiny stellates to superficial pyramidal populations. Exploratory regressions linked greater thalamocortical delay during deep sleep to greater sleep problems (β=0.34, pFDR=0.006), and AMPA-mediated excitation of interneurons during wakefulness to anxiety symptoms (β=−0.32, pFDR=0.032). These findings implicate NMDA receptor hypofunction as a key mechanism in 22q11.2DS and suggest it may serve as a treatment target. We further show that DCM-based virtual pharmacology can simulate drug-level interventions, and we are now testing whether NMDA receptor modulation restores network activity in preclinical models (e.g., mouse models of 22q11.2DS).
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | In Press |
| Schools: | Schools > Psychology Schools > Medicine |
| Publisher: | Springer Nature [academic journals on nature.com] |
| ISSN: | 2158-3188 |
| Date of First Compliant Deposit: | 8 September 2026 |
| Date of Acceptance: | 10 August 2026 |
| Last Modified: | 08 Sep 2026 15:15 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/189456 |
Actions (repository staff only)
![]() |
Edit Item |





Altmetric
Altmetric